Enanta Pharmaceuticals (ENTA)Chief Medical Officer sold ~$7K

~$7K

Approx. value · 866 sh @ $8.06

18K

Holds after · shares reported

Traded

Dec 6, 2024

Filed

Dec 10, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 6, 2024 · this disclosureInsiderOfficer sold ~$7K of ENTA shares in the open market

What came next

1. Dec 6, 2024Insider · 5 peopleInsiders: 5 sales (~$120K)
2. Feb 12, 2025InsiderCEO purchased ~$256K of ENTA shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Enanta Pharmaceuticals

For Enanta Pharmaceuticals, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ENTA page.

Other recent filings by Scott T. Rottinghaus, Chief Medical Officer

• SEC Form 4 at Enanta Pharmaceuticals (ENTA)Dec 5, 2025

The full history of Scott T. Rottinghaus, Chief Medical Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Enanta Pharmaceuticals

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRFeb 13, 2026
• SEC Form 4Dec 5, 2025
• SEC Form 4Dec 5, 2025
• SEC Form 4Dec 5, 2025
• SEC Form 4Dec 5, 2025

Everything OQRO holds on this company is on its ENTA page.